The Effect of β-hydroxy-β-methylbutyrate Supplementation on Physical Capacity and Body Composition in Trained Athletes

NCT ID: NCT03028649

Last Updated: 2017-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2014-02-28

Brief Summary

The purpose of this study was to verify the effect of 12-week with β-hydroxy-β-methylbutyrate (HMB) and a placebo (PLA) supplementation on body composition, anaerobic and aerobic capacity, as well as concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Detailed Description

The effect of HMB supplementation is of great interest in sport. In view of the inconclusive character of the results of the studies conducted to date and of a relatively low number of studies investigating the effectiveness of HMB supplementation over a longer period on a large population of trained athletes, the aim of this study was to verify the effect of 12-week with HMB and a placebo supplementation on body composition, anaerobic and aerobic capacity, as well as concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Conditions

Sport; Supplements; Supplementation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

β-hydroxy-β-methylbutyrate (HMB)

Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.

Interventions:

The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.

Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced.

Group Type: EXPERIMENTAL

β-hydroxy-β-methylbutyrate and a placebo supplementation

Intervention Type: DIETARY_SUPPLEMENT

Placebo (maltodextrin)

Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.

Interventions:

The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.

Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced.

Group Type: PLACEBO_COMPARATOR

β-hydroxy-β-methylbutyrate and a placebo supplementation

Intervention Type: DIETARY_SUPPLEMENT

Interventions

β-hydroxy-β-methylbutyrate and a placebo supplementation

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• written consent to participate,
• male
• a current medical clearance to practice sports,
• training experience: at least 5 years,
• minimum of 6 workout sessions a week (minimum 3 in the practiced sports discipline).

Exclusion Criteria

• current injury,
• any health-related contraindication,
• declared general feeling of being unwell,
• unwilling to follow the study protocol.

• Minimum Eligible Age: 17 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Poznan University of Life Sciences

OTHER

Sponsor Role: collaborator

National Science Centre, Poland

OTHER_GOV

Sponsor Role: collaborator

Poznan University of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Krzysztof Durkalec-Michalski

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jan Jeszka, Professor

Role: STUDY_CHAIR

Department of Hygiene and Human Nutrition, Poznan University of Life Sciences, Poznan, Poland

Locations

Poznan University of Life Sciences, ul.Wojska Polskiego 31

Poznan, Wielkopolska, Poland

Countries

Poland

Other Identifiers

NN312262340

Identifier Type: -

Identifier Source: org_study_id